UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome

Startin, CM; Hamburg, S; Hithersay, R; Al-Janabi, T; Mok, KY; Hardy, J; LonDownS Consortium, .; (2018) Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome. Alzheimer's & Dementia 10.1016/j.jalz.2018.08.009. (In press). Green open access

[thumbnail of Hardy_Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome_VoR.pdf]
Preview
Text
Hardy_Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome_VoR.pdf - Published Version

Download (483kB) | Preview

Abstract

INTRODUCTION: Down syndrome (DS) is associated with an almost universal development of Alzheimer's disease. Individuals with DS are therefore an important population for randomized controlled trials to prevent or delay cognitive decline, though it is essential to understand the time course of early cognitive changes. METHODS: We conducted the largest cognitive study to date with 312 adults with DS to assess age-related and Alzheimer's disease-related cognitive changes during progression from preclinical to prodromal dementia, and prodromal to clinical dementia. RESULTS: Changes in memory and attention measures were most sensitive to early decline. Resulting sample size calculations for randomized controlled trials to detect significant treatment effects to delay decline were modest. DISCUSSION: Our findings address uncertainties around the development of randomized controlled trials to delay cognitive decline in DS. Such trials are essential to reduce the high burden of dementia in people with DS and could serve as proof-of-principle trials for some drug targets.

Type: Article
Title: Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.jalz.2018.08.009
Publisher version: https://doi.org/10.1016/j.jalz.2018.08.009
Language: English
Additional information: © 2018 The Authors. This is an open access article under the CC BY license(http://creativecommons.org/licenses/by/4.0/)
Keywords: Alzheimer's disease, Cognitive decline, Dementia, Down syndrome, Preclinical, Prodromal, Randomized controlled trials
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Department of Neuromuscular Diseases
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > UK Dementia Research Institute
URI: https://discovery.ucl.ac.uk/id/eprint/10064449
Downloads since deposit
72Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item